Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
05/2003
05/15/2003WO2003040107A1 Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity
05/15/2003WO2003040105A1 Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same
05/15/2003WO2003040102A1 Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors
05/15/2003WO2003040101A1 Anthranilic acid amides and pharmaceutical use thereof
05/15/2003WO2003040098A1 Novel metalloproteinase inhibitors
05/15/2003WO2003040097A1 Nitrogenous compounds, production process, and method of use thereof
05/15/2003WO2003040080A2 Lipoxin a4 analogs
05/15/2003WO2003040077A1 Combretastatin a-4 derivatives having antineoplastic activity
05/15/2003WO2003039600A1 Selective treatment of il-13 expressing tumors
05/15/2003WO2003039599A1 Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
05/15/2003WO2003039592A2 Cellular vaccines comprising adjuvants
05/15/2003WO2003039591A2 Allogenic vaccine that contains a costimulatory polypeptide-expressing tumor cell
05/15/2003WO2003039576A1 Psp-94: use for treatment of hypercalcemia and bone metastasis
05/15/2003WO2003039574A1 Endophilin homologous proteins involved in the regulation of energy homeostasis
05/15/2003WO2003039571A1 Improved use of antitumoral compound in cancer therapy
05/15/2003WO2003039568A1 Anticancer compositions
05/15/2003WO2003039567A1 Anticancer compositions
05/15/2003WO2003039564A1 Selective targeting of apoptotic cells
05/15/2003WO2003039560A1 Antitumor agent containing lactic acid oligomer mixture
05/15/2003WO2003039551A1 Combination therapy comprising zd6474 and a taxane
05/15/2003WO2003039550A1 Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases
05/15/2003WO2003039545A2 Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers
05/15/2003WO2003039544A1 Naphtyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
05/15/2003WO2003039543A1 Derivatives of phenoxy-n-'4-(isothiazolidin-1,1-dioxid-2yl)pheny!-valerian- acid amide and other compounds as inhibitors of the coagulation factor xa in the treatment of thromboembolic diseases and tumors
05/15/2003WO2003039539A2 Use of endothelin receptor antagonists in the treatment of tumour diseases
05/15/2003WO2003039533A1 Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
05/15/2003WO2003039526A1 Treatment of breast cancer
05/15/2003WO2003039523A2 OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES
05/15/2003WO2003039520A1 Orodispersible tablet having high homogeneity and the preparation method thereof
05/15/2003WO2003039486A2 Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
05/15/2003WO2003039484A2 Novel compositions and methods for cancer
05/15/2003WO2003039479A2 Polymeric thiol-linked prodrugs
05/15/2003WO2003039475A2 Methods of identifying and using modulators of fractalkine receptor
05/15/2003WO2003039473A2 Method for treating or preventing inflammatory diseases
05/15/2003WO2003039472A2 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
05/15/2003WO2003039466A2 Method of treating estrogen responsive breast cancer
05/15/2003WO2003039462A2 B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies
05/15/2003WO2003039460A2 Mitotic kinesin inhibitors
05/15/2003WO2003039458A2 TREATMENT OF HUMAN CANCER WITH ADENOVIRAL VECTOR EXPRESSING TNF-α
05/15/2003WO2003039446A2 Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase
05/15/2003WO2003039444A2 Topical use of cytokines and/or chemokines for the treatment of viral or mykotic skin diseases or tumoral diseases
05/15/2003WO2003039437A2 Orally administered pharmaceutical preparation comprising liposomically encapsulated paclitaxel
05/15/2003WO2003039434A2 Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and products thereof
05/15/2003WO2003039342A2 Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
05/15/2003WO2003039225A2 Antigen arrays comprising rankl for treatment of bone disease
05/15/2003WO2003025171A3 Modulation of retinoic acid receptor gene expression and therapeutic uses thereof
05/15/2003WO2003020754A3 Inhibition of replication factor c
05/15/2003WO2003011336A3 Liposomes prepared from the extractable lipids from a mycobacterium
05/15/2003WO2003006063A3 Formulation comprising fulvestrant
05/15/2003WO2003005965A3 Modulators of ceramidase and methods of use based thereon
05/15/2003WO2002097032A3 Proteins associated with cell growth, differentiation, and death
05/15/2003WO2002083179A3 Fusion proteins
05/15/2003WO2002067961A3 Therapeutic uses of herbal compositions
05/15/2003WO2002064795A3 Putative human enzymes
05/15/2003WO2002059156A3 Therapeutic compounds structurally-linked to bacterial polypeptides
05/15/2003WO2002058679A3 Antiangiogenic compounds and an assay for inhibitors of cell invasion
05/15/2003WO2002056027A3 Regulation of neutral development by daedalos
05/15/2003WO2002055108A9 Targeted modification of intracellular compounds
05/15/2003WO2002048366A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
05/15/2003WO2002048365A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
05/15/2003WO2002040654A3 A human serpin secreted from lymphoid cells lsi-01
05/15/2003WO2002040533A1 Radiosensitivity enhancers in radiotherapy for cancer and nucleic acids and proteins enhancing radiosensitivity
05/15/2003WO2002040016A8 Association of calpain inhibitors and reactive oxygen species trapping agents
05/15/2003WO2002030462A9 Hedgehog antagonists, methods and uses related thereto
05/15/2003WO2002029031A3 Isoprenoid-dependent ras anchorage (idra) proteins
05/15/2003WO2002026717A8 Hydroxy acid integrin antagonists
05/15/2003WO2002018407A9 Antisense oligonucleotides against vanilloid receptor 1
05/15/2003WO2002000611A8 Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists
05/15/2003WO2001080832A3 Administration of a thiol-based chemoprotectant compound
05/15/2003WO2001071309A3 Methods and reagents for regulation of cellular responses in biological systems
05/15/2003US20030093819 Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
05/15/2003US20030092917 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as portein kinase inhibitors
05/15/2003US20030092909 Cyclin-dependent kinase inhibitor; antitumor, anticancer agents
05/15/2003US20030092908 Autoimmune diseases; rheumatic diseases; multiple sclerosis; inflammatory bowel disease; immunosuppressants
05/15/2003US20030092894 Conjugated antigen for use as tool in the treatment of cancer
05/15/2003US20030092891 Expressed ligand - vascular intercellular signalling molecule
05/15/2003US20030092800 Sustained release; drug delivery
05/15/2003US20030092771 Inhibitors of transcription factor NF-kappaB
05/15/2003US20030092762 Anti-inflammatory nitro and thia-fatty acids
05/15/2003US20030092756 Antiproliferative agents
05/15/2003US20030092751 3-glyoxlylamideindoles for treating cancer
05/15/2003US20030092748 Benzenesulfonamide derivatives and their use as MEK inhibitors
05/15/2003US20030092738 Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity
05/15/2003US20030092736 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
05/15/2003US20030092732 Eating disorders; dietetics; antiinflammatory agents; autoimmune diseases
05/15/2003US20030092729 Anticancer agents; modulating glycoprotein
05/15/2003US20030092727 Hydroxamic and carboxylic acid derivatives
05/15/2003US20030092721 Antiinflammatory agents; rheumatic diseases
05/15/2003US20030092714 Heterocyclic inhibitors of ERK2 and uses thereof
05/15/2003US20030092713 Antiinflammatory agents; antiallergens; psychological disorders
05/15/2003US20030092712 Antiinflammatory agents; rheumatic diseases
05/15/2003US20030092711 Contraceptives; hormone replacement therapy
05/15/2003US20030092707 Treatment of breast cancer
05/15/2003US20030092703 Caspase inhibitors and uses thereof
05/15/2003US20030092697 Antidiabetic, antilipemic agents; cardiovascular disorders; anticancer agents
05/15/2003US20030092695 Hormone inhibitors; therapy for sexual disorders
05/15/2003US20030092678 Muscle relaxants, controlling immunology, sexual disorders, rheumatic diseases
05/15/2003US20030092676 Agents and method for the treatment of proliferative diseases
05/15/2003US20030092655 Delivery system for nucleic acids
05/15/2003US20030092638 Protopanaxadiol and protopanaxatriol and their use as anti-cancer agents
1 ... 1563 1564 1565 1566 1567 1568 1569 1570 1571 1572 1573 1574 1575 1576 1577 1578 1579 1580 1581 1582 1583 ... 2211